FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Cisatracurium Besylate Injection
Status: Discontinuation
»Therapeutic Categories: Analgesia/Addiction

Expand all

Hospira, Inc., a Pfizer Company (New 05/06/2026)

Company Contact Information:
844-646-4398

Presentation	Posting Date	Related Information
Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01)	05/06/2026	Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug
Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)	05/06/2026	Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug